Zhigang Liu, James L Alexander, Kaixing Le, Xin Zhou, Hajir Ibraheim, Sulak Anandabaskaran, Aamir Saifuddin, Kathy Weitung Lin, Leon R McFarlane, Laura Constable, Rocio Castro Seoane, Nikhil Anand, Claire Bewshea, Rachel Nice, Andrea D'Mello, Gareth R Jones, Sharmili Balarajah, Francesca Fiorentino, Shaji Sebastian, Peter M Irving, Lucy C Hicks, Horace Rt Williams, Alexandra J Kent, Rachel Linger, Miles Parkes, Klaartje Kok, Kamal V Patel, Julian P Teare, Daniel M Altmann, Rosemary J Boyton, Ailsa L Hart, Charlie W Lees, James R Goodhand, Nicholas A Kennedy, Katrina M Pollock, Tariq Ahmad, Nick Powell
BACKGROUND: Patients with inflammatory bowel disease (IBD) receiving anti-TNF and JAK-inhibitor therapy have attenuated responses to COVID-19 vaccination. We aimed to determine how IBD treatments affect neutralising antibody responses against the Omicron BA.4/5 variant. METHODS: In this multicentre cohort study, we prospectively recruited 340 adults (69 healthy controls and 271 IBD) at nine UK hospitals between May 28, 2021 and March 29, 2022. The IBD study population was established (>12 weeks therapy) on either thiopurine (n = 63), infliximab (n = 45), thiopurine and infliximab combination therapy (n = 48), ustekinumab (n = 45), vedolizumab (n = 46) or tofacitinib (n = 24)...
October 2023: EClinicalMedicine